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Use of pharmacotherapy during pregnancy is common and increasing. Physiologic changes
during pregnancy may significantly alter the overall systemic drug exposure, necessitating
dose changes. A search of PubMed for pharmacokinetic clinical trials showed 494 publi-
cations during pregnancy out of 35,921 total pharmacokinetic published studies (1.29%),
from the late 1960s through August 31, 2013. Closer examination of pharmacokinetic stud-
ies in pregnant women published since 2008 (81 studies) revealed that about a third of
the trials were for treatment of acute labor and delivery issues, a third included studies
of infectious disease treatment during pregnancy, and the remaining third were for varied
ante-partum indications. Approximately, two-thirds of these recent studies were primarily
funded by government agencies worldwide, one-quarter were supported by private non-
profit foundations or combinations of government and private funding, and slightly <10%
were supported by pharmaceutical industry. As highlighted in this review, vast gaps exist
in pharmacology information and evidence for appropriate dosing of medications in preg-
nant women. This lack of knowledge and understanding of drug disposition throughout
pregnancy place both the mother and the fetus at risk for avoidable therapeutic misadven-
tures – suboptimal efficacy or excess toxicity – with medication use in pregnancy. Increased
efforts to perform and support obstetric dosing and pharmacokinetic studies are greatly
needed.
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INTRODUCTION
Use of pharmacotherapy during pregnancy is common and
increasing. From 1976 to 2008, the average number of medica-
tions (prescription and non-prescription) used during the first
trimester increased from 1.6 to 2.6; this is an increase of approx-
imately 60% (1). More recently, from 2006 to 2008 over 80% of
women reported using at least one medication during the first
trimester and over 90% reported using at least one medication at
any point during the pregnancy (1). Given that during this time
frame approximately 6.6 million pregnancies occurred per year in
the United States (U.S.) (2), the issue of pharmacotherapy during
pregnancy clearly has widespread relevance.
Increased use of medications during the first trimester is partic-
ularly concerning as this is a crucial period for organogenesis and,
further, many women may be unaware of their pregnancy dur-
ing this time. A recent review of 172 drugs approved by the Food
and Drug Administration (FDA) from 2000 to 2010, conducted
using the Teratogen Information System (TERIS), revealed insuf-
ficient data to determine teratogenic risk for nearly 98% of these
drugs; over 70% actually had no pregnancy-related data available
(3). Understanding teratogenic risk is important yet unfortunately
understudied, especially for newer agents.
Despite the lack of safety data, often medication administration
during pregnancy is unavoidable, with the benefits of treatment
outweighing the possible risks. When medications need to be
used during pregnancy, another concerning issue is the deficit
of knowledge as to the proper dosing of pharmacotherapy dur-
ing pregnancy. Understanding how to dose medications during
pregnancy is crucial in order to ensure that the dose achieves
therapeutic but not toxic plasma concentrations for both mater-
nal and fetal wellbeing. Given the high and increasing rates of
pharmacotherapy usage during pregnancy, gaps in pharmacol-
ogy and appropriate dosing knowledge in pregnant women place
both the mother and the fetus at risk for avoidable therapeutic
misadventures.
The many physiologic changes throughout pregnancy affect
pharmacokinetic parameters for pharmacotherapy administered
during this time. The four primary processes of concern in phar-
macokinetics, that is absorption, distribution, metabolism, and
excretion, may all be influenced. Such pregnancy-related changes
include changes in gastrointestinal motility and pH impacting
absorption, expansion of total body water and plasma volume,
and decreased concentrations of drug binding proteins affecting
distribution, changes in drug metabolism rates by cytochrome
P450 (CYP) and other metabolizing and transport enzymes, and
increased glomerular filtration rate affecting urinary excretion (4).
These various changes are not constant but rather fluctuate accord-
ing to different patterns throughout the timeframe of pregnancy
(4). These physiologic changes may have additive, synergistic, or
competing effects on overall drug exposure. The clinical signifi-
cance of these changes varies by drug, depending on the magnitude
of the effect and the therapeutic window of the drug. The impact
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on overall drug exposure for any given drug is difficult to predict.
To appropriately and safely dose drugs during pregnancy, these
pharmacokinetic changes must be understood. Determination of
the corresponding pharmacodynamic changes in pregnancy is also
essential to understanding the pharmacokinetic changes in terms
of implications for dosing. The objective of this focused review
is to focus on the pharmacokinetic aspect to examine trends over
time in the availability of maternal pharmacokinetic and dosing
data for medications during pregnancy, to describe the drug classes
or disease states, which have been studied for dosing determina-
tion to some degree during pregnancy, and to characterize sources
of support for pharmacokinetic studies in pregnant women.
METHODS
A literature search was conducted within PubMed to assess the
number of pharmacokinetic trials in pregnancy conducted over
time and to determine which classes of drugs have been studied.
A search of PubMed was performed for the terms “pharmaco-
kinetics” and “pregnancy” with filters for “human” (species) and
publication date through August 31, 2013 with no start date spec-
ified. “Pharmacokinetics” and “pregnancy” were not entered as
MeSH terms after finding that many articles directly addressing
pharmacokinetics were not indexed to have this as a MeSH term
but rather had something more specific listed as a MeSH term
instead, such as “adenine/pharmacokinetics.” A publication type
filter was used for “clinical trial” and, separately, to search for all
types except “case report” and “review.”
The results from this search strategy were stratified by year.
Articles with electronic publication (e-publication) ahead of print
were categorized in the year of print publication and not e-
publication to avoid double-counting. All of the results categorized
as clinical trials beginning with January 1, 2008 were more closely
examined as follows. Those articles unrelated to the actual time
period of pregnancy, despite being important to the larger field of
women’s health, were excluded for the purposes of this review.
Examples of such excluded topics include in vitro fertilization
(IVF) treatments, breastfeeding and other postpartum issues, and
sexually transmitted diseases outside of pregnancy. Articles per-
taining to pregnancy but unrelated to pharmacotherapy, including
environmental exposures,were also excluded. Finally, articles com-
pletely unrelated to pregnancy or humans and in vitro studies that
appeared in the search results were excluded.
Additionally, a list of publications affiliated with the Obstetric-
Fetal Pharmacology Research Unit (OPRU) network, provided on
their website, was reviewed for additional publications and to test
the completeness of the PubMed search strategy. Publications from
2008 through August 31, 2013 were manually reviewed for inclu-
sion based on the same criteria as described above for the PubMed
search results.
The non-excluded results from both the clinical trial PubMed
and OPRU list searches were classified into broad categories as
follows: (1) medication administration and parameter measure-
ments occurring exclusively during labor and delivery and typi-
cally involving pain control or infectious disease (ID) prophylaxis
[antiretrovirals (ARVs), antibiotics], (2) medications for treat-
ment or prevention of pre-eclampsia or hemolysis, elevated liver
enzymes, low platelets (HELLP) syndrome, and tocolytic therapy,
(3) ARV regimens during pregnancy excluding one-time doses
administered during labor, (4) non-HIV ID pharmacotherapy
during pregnancy but again excluding doses given solely around
the time of labor for prophylactic purposes, (5) vitamins and min-
erals during pregnancy (except magnesium for pre-eclampsia),
and (6) studies of medications during pregnancy that do not fit
into the other categories. Of the described six categories, categories
1–2 include studies focusing on acute and subacute conditions sur-
rounding the time of delivery. Categories 3–6 focus on conditions
requiring treatment at any time throughout pregnancy. Most stud-
ies involving a single dose at time of labor and delivery were placed
in categories 1–2. However, a few such studies were placed into the
categories 3–6 if they involved drug administration immediately
prior to delivery but in a patient with scheduled cesarean and no
onset of labor. This decision was made because the goal of such
studies was in part to determine third-trimester (pre-labor) phar-
macokinetic parameters. Since the dose was administered so close
to delivery in such cases, fetal exposure could simultaneously be
ascertained.
For the studies published after January 1, 2008, primary sources
of funding were determined where possible. Acknowledgments
and listings of funding support in the full texts of the articles were
examined to categorize primary funding sources.
Finally, out of concern that the PubMed“clinical trial”filter may
exclude some otherwise relevant articles, a filter for all publication
types except “review” and “case report” was placed and a thor-
ough manual review was performed for 2012 and 2013 (through
August 31). This was performed to ascertain the rough proportion
of total articles captured utilizing the“clinical trial”filter and allow
for potential extrapolation.
RESULTS
The overall search of PubMed as described and using the “clini-
cal trial” filter yielded 464 results. Without the term “pregnancy”
this same search had 35,921 results, indicating that only 1.29%
(464/35,921) of the pharmacokinetic studies found in the search
involved pregnant women. As can be visualized in Figures 1 and 2,
absolute number of pharmacokinetic studies, both with and with-
out pregnancy data, have steadily increased over the past four
decades with particularly large increases from the mid-1980s to
mid-1990s. However, as shown in Figure 3 the proportion of
these studies involving pregnancy has been relatively constant
since around 1990; years prior to the mid-1980s had significant
fluctuations in this proportion as expected given the low absolute
values. The year 2013 is displayed in Figure 1 for informational
purposes; note that it only includes those articles indexed in MED-
LINE by August 31, 2013. The number of articles for 2013 were
not adjusted to account for the partial year as scaling for 8 of
12 months did not seem reasonable given the inconsistent multi-
month delay between publication and appearance in PubMed.
When searching for all except “review” and “case report” publica-
tion types, the total number of articles was 156,539 with 3633 of
these in pregnancy (2.3%). However, as per the manual review of
a subset of this broader search described below, most of the arti-
cles when searching by “clinical trial” were relevant whereas most
found by the broader search were excluded. Hence, the percent-
age of 1.29 from the narrower search is likely more reliable and
Frontiers in Pediatrics | Obstetric and Pediatric Pharmacology February 2014 | Volume 2 | Article 9 | 2
McCormack and Best Lack of obstetric pharmacology studies
FIGURE 1 | Number of pharmacokinetic clinical trials conducted in
pregnancy. The year 2013 includes those articles index for MEDLINE by
August 31, 2013 only. This figure displays the absolute number of articles
meeting the search terms, displayed by year.
FIGURE 2 | Number of pregnancy and non-pregnancy pharmacokinetic
clinical trials. The year 2013 includes those articles index for MEDLINE by
August 31, 2013 only. This figure displays the number of pregnancy
pharmacokinetic articles along with all pharmacokinetic articles (pregnancy
search term excluded) found to otherwise match the search terms
specified.
the findings from the broader search were not further stratified by
year. Additional pregnancy studies identified through the OPRU
listing search are not included in these overall percentages as there
was not a comparable method available to check for additional
studies in PubMed associated with the overall (pregnancy plus
non-pregnancy) count.
When narrowing the above search, limited to “clinical trial,” to
the time frame of January 1, 2008 to August 31, 2013, 134 articles
remained. Of these,59 were excluded based on the criteria specified
in the Section “Methods” above, leaving 75 for further classifica-
tion. Of the 75 remaining studies, 8 were drug studies that did not
measure drug concentrations and appeared unrelated to pharma-
cokinetics despite this being one of the search terms. These studies
typically involved measurement of an outcome (e.g., change in
FIGURE 3 | Proportions of pharmacokinetic clinical trials conducted in
pregnancy. The year 2013 includes those articles index for MEDLINE by
August 31, 2013 only. This figure shows the percentage of pregnancy
pharmacokinetic articles compared to all pharmacokinetic articles published
since the early 1990s.
blood pressure) in response to drug dosing adjustments without
measuring the drug concentration itself. Given that these studies
did not meet the exclusion criteria and still contribute to improved
pharmacotherapy in pregnancy, they were included in this review
but noted accordingly in Table 1.
Six additional relevant studies, approximately one per year,were
identified by review of the OPRU studies listing. These were not
found by PubMed only because they were not indexed as “clinical
trial” (publication type), but upon careful review “clinical trial”
indexing would have been appropriate. This resulted in a total of
81 studies included from the two search methods.
Approximately one-third of studies (26/81) classified were
focused on pharmacokinetic issues during or immediately pre-
ceding labor; specifically, 19 studies were during labor and delivery
and 7 more focused on pre-eclampsia and HELLP management
prior to delivery or tocolytics to delay delivery. In comparison, 55
studies addressed medications given chronically during pregnancy.
Of the chronic medications, 16 of the 55 studies were for HIV treat-
ment and vertical transmission prevention. More detailed results
of this classification are displayed in Table 1 and Figure 4.
Within the non-HIV ID category, the sub-classification by
year is as follows. No articles have been published yet in 2013.
In 2012 azithromycin was studied (47). 2011 included one
study of metronidazole for bacterial vaginosis (48), one study of
oseltamivir (49), and two studies of anti-malarial regimens (50,
51). In 2010 and 2009 two studies of anti-malarial regimens in
pregnancy were published each year (52–55). 2008 had one study
of an anti-malarial regimen (56) and one of amoxicillin in preterm
premature rupture of membranes (57).
The final category, containing all drug classes given throughout
pregnancy but not related to IDs, contained a sub-classification
of available studies by year as follows. In the first 8 months of
2013, the only medication studied was doxylamine/pyridoxine
for nausea/vomiting in pregnancy (61). In 2012, these medica-
tions included metformin for Type 2 diabetes in obese pregnant
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Table 1 | Classification of search results for recent clinical trials of pharmacokinetics and pregnancy.
Year Total (PubMed+
OPRU)
Acute/subacute Chronic
Intra-
partum
Late ante-
partum
ARVs ante-
partum
Other ID
ante-partum
Vitamins/minerals
ante-partum
Other medications
ante-partum
2013 (1/1–8/31 only) 9 3 2 2 0 1 1
2012 14 2 2a 4 1 1a 4
2011 17 4 0 4 4 0 5
2010 11 4b 1 1 2 0 3
2009 16 3 1 2 2 1 7b
2008 14 3a 1 3 2 0 5a
Total (1/2008–8/2013) 81 19 7 16 11 3 25
Data for 2013 only includes those articles indexed for MEDLINE as “clinical trial” (publication type) by August 31, 2013. The “intra-partum” category includes med-
ications given at the time of delivery, typically for pain control or infectious disease prophylaxis. The “late ante-partum” category includes pharmacotherapy given for
pre-eclampsia; management of syndrome of hemolysis, elevated liver enzymes, and low platelets (HELLP); or to induce tocolysis. The remaining categories include
medications administered earlier in pregnancy (i.e., prior to labor/delivery) only.
ARVs, antiretrovirals; ID, infectious disease. References for each column: intra-partum (5–23), late ante-partum (24–30), ARVs (31–46), other ID (47–57),
vitamins/minerals (58–60), other medications (61–85).
aOne study in this category did not measure drug concentrations.
bTwo studies in this category did not measure drug concentrations.
FIGURE 4 |Trends for classification of search results for recent clinical
trials of pharmacokinetics and pregnancy. Data for 2013 only includes
those articles indexed for MEDLINE by August 31, 2013. The “intra-partum”
category includes medications given at the time of delivery, typically for pain
control or infectious disease prophylaxis. The “late ante-partum” category
includes pharmacotherapy given for pre-eclampsia; management of
syndrome of hemolysis, elevated liver enzymes, and low platelets (HELLP);
or to induce tocolysis. The remaining categories include medications
administered earlier in pregnancy (i.e., prior to labor/delivery) only.
women (62), tacrolimus (63), 17-hydroxyprogesterone for pre-
vention of preterm labor in patients at risk (64), and doxorubicin
and ifosfamide for high-grade sarcomas during pregnancy (65).
In 2011, the medications were buprenorphine for opioid depen-
dence treatment (66), two studies of methadone written by the
same authors (67, 68), intravenous immunoglobulin (IVIG) (69),
and labetalol (70). 2010 had one study of fluoxetine (71), one of
metformin (72), and one of glucose kinetics (73). In 2009, studies
addressed dydrogesterone to prevent miscarriage in patients with
second trimester vaginal bleeding (74), doxylamine/pyridoxine for
nausea/vomiting of pregnancy (75), sumatriptan/naratriptan (76),
safety of serotonin reuptake inhibitors (SSRIs)/serotonin norep-
inephrine reuptake inhibitors (SNRIs) (77), glyburide for gesta-
tional diabetes (78), lamotrigine for epilepsy (79), and clonidine
(80). The drugs studied in 2008 were sertraline (81), enoxaparin
(82), glyburide (83), aspirin in patients whose pregnancy was
achieved via IVF (84), and finally midazolam and digoxin (as probe
substrates studying CYP3A enzymes and P-glycoprotein) (85).
When broadening the search criteria to include all publication
types except for case reports and reviews, 634 additional articles
were found from January 1, 2008 through August 31, 2013. Nar-
rowing from January 1, 2012 to August 31, 2013 resulted in 180
additional articles. When manually reviewing each of these 180
results for original data relevant to dosing during pregnancy, only
18 were relevant (14 in 2012 and 4 through August 2013). Com-
bining with the 23 relevant articles found by searching for “clinical
trial” yields a total of 41 relevant articles during the time period
and indicates that the broader count for the other years reported
in Table 1 may be increased by approximately 44%. The additional
relevant studies included three studies related to intra-partum pain
management (86–88), four on ARVs ante-partum (89–92), six on
antimalarials (93–98) of which many are by the same authors,
one on vitamin D (99), and five on other ante-partum pharma-
cotherapy. Of these latter four studies, one study addressed anti-D
IgG dosing (100), one addressed anti-tumor necrosis factor for
inflammatory bowel disease (101), and two modeled activities of
CYP enzymes (102, 103).
Primary funding sources for the clinical trials published since
January 1, 2008 were determined if available. Of the 81 articles
included, all except for 13 articles stated their source of fund-
ing. See Figure 5 for the approximate distribution of funding
sources.
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FIGURE 5 | Distribution of primary funding sources. For clinical trials
with funding source information provided, the number of studies primarily
funded by each source is displayed.
Of the 68 clinical trials with explicit funding information, 30/68
(44%) were funded via U.S. government organizations; one arti-
cle was funded by U.S. Department of Agriculture (USDA) and
29 were by various institutes of the National Institutes of Health
(NIH). The primary NIH institutes involved were the National
Institute of Allergy and Infectious Diseases (NIAID) and the Eunice
Kennedy Shriver National Institute of Child Health and Human
Development (NICHD); other supporting institutes included the
National Institute of Diabetes and Digestive and Kidney Diseases
(NIDDK), the National Institute of Mental Health (NIMH), the
National Institute on Drug Abuse (NIDA), and the National Cen-
ter for Research Resources (NCRR). The OPRU network, funded
by the NICHD was, as per their listing of affiliated publications,
associated with 11 of the studies (26, 27, 48, 49, 61, 63, 64, 72, 78, 80,
83). Some of these were explicitly sponsored by OPRU as per the
author listing or funding acknowledgment; others stated a non-
governmental source of funding but presumably were included in
this listing based on author affiliation.
Another 14/68 (21%) of the studies were funded by governmen-
tal funding from outside the U.S., including Brazil (five studies),
Australia (two studies), Belgium, Canada, Germany, Hong Kong,
Japan, Netherlands, and Switzerland. An additional study was a
joint effort of government funding from the U.S. (NIH), France,
and Thailand.
Drug companies directly funded 6/68 (8.8%) of studies, exclud-
ing legally independent foundations that receive support from
drug companies. Private non-profit foundations (U.S. and abroad)
funded 12/68 (18%) of the studies, and combinations of public
and private funding were responsible for the remaining 5/68 (7%)
studies.
DISCUSSION
This review found that only 1.29% of pharmacokinetic clinical tri-
als indexed in PubMed provide data for pregnant women. A search
for pregnancy rates within the National Vital Statistics Reports, at
present containing data through 2008, revealed a yearly pregnancy
rate for females in the U.S., ranging from 10.4 to 10.7% (2). This
would roughly correspond to a population of yearly pregnancy
rate ranging from 5.2 to 5.4%. These rates are up to five times
higher than the rates of pregnancy-related studies available dur-
ing this same time frame, which were 1.1–1.6% as per this review.
The decision to use medications during pregnancy should be based
on a complete understanding of the risks and benefits and should
include an understanding of how to optimally dose these med-
ications in this population. Unfortunately, the knowledge of the
risks, benefits, and optimal dosing are often incomplete; during
pregnancy, these knowledge gaps in many cases are vast.
This review found that relative to other drug classes, the ARVs
have a larger number (16/81:20% since 2008) of pharmacokinetic
clinical trials during pregnancy. This is perhaps in part due to
explicit devotion of resources and the medical community’s agree-
ment and public acceptability that these medications are not only
for maternal wellbeing but to prevent transmission of HIV to the
fetus. These HIV studies have found that doses for some med-
ications but not others do need to be altered during pregnancy.
The findings of the pharmacology studies in pregnant women
with HIV highlight the need for studies of the multitudes of other
medications and drug classes being used by pregnant women.
Over time many women are postponing childbearing to an
older age (2), increasing the risk of concomitant chronic health
issues throughout pregnancy. Further, advances in reproductive
technology can potentially enable women to become pregnant
who would not have been healthy enough otherwise. Certain
chronic conditions such as Type 2 diabetes are frequently appear-
ing at younger ages than they have in the past and may exist
prior to pregnancy (104–106). All of these issues increase the
risk that a pregnant female will have a chronic medical condi-
tion prior to pregnancy that necessitates chronic pharmacotherapy
during pregnancy. Such pharmacotherapy requires knowledge of
the proper dosing in order to achieve the proper drug concentra-
tions for efficacious management of the condition and to prevent
poor fetal outcomes associated with poor maternal disease control.
This raises the question of which medical conditions are seen
most frequently in the childbearing population and if sufficient
evidence exists to treat these conditions appropriately during
pregnancy. A recent study surveyed mothers to determine which
medications they had used during the first trimester of pregnancy
(107). The majority of oral medications in the list generated by that
study fell into the categories of antibiotics, analgesics, anti-emetics,
diabetes treatment (metformin and insulin), and psychiatric med-
ications (primarily antidepressants) (107). Of these, data were
significantly lacking for the psychiatric medications as well as for
some of the antibiotics. Proper treatment of both infections and
psychiatric illnesses is crucial in pregnancy for both maternal and
fetal wellbeing – perhaps even more crucial than in non-pregnant
populations.
For the specific psychiatric example of depression,prevalence of
depression from 2007 to 2010 in females ages 18–39 was approx-
imately 10% (108); this encompasses most of the childbearing
years. In the next age category, ages 40–59, this rate was simi-
lar at 12% (108). However, for ages ≥60, the depression rate in
females drops to 7% (108). Based on these prevalence rates, the
common usage of antidepressants during pregnancy is not surpris-
ing. However, over the time period closely examined in this review
(January 2008 to August 2013), only three pharmacokinetic studies
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were published pertaining to psychiatric medications. These stud-
ies only addressed selective SSRIs and one SNRI. Further, while
all three studies measured maternal SSRI or SNRI concentrations,
only two (71, 81) were designed to determine maternal pharmaco-
kinetic parameters and proper dosing. The third focused on cor-
relating the maternal drug concentrations to cord concentrations
and neonatal behavioral outcomes (77). Increased inclusion of the
pregnant population in pharmacokinetic studies of antidepres-
sants is a necessary change in order to address this knowledge gap.
In addition to the need for increased awareness of the scope of
this problem of insufficient pharmacokinetic trials during preg-
nancy, increased incentive for government and non-government
funding of these trials is also needed. Currently, the pharmaceu-
tical industry has no incentive or mandate to fund trials that
include pregnant patients as part of the drug approval process,
and, as revealed, the drug companies were the primary spon-
sors of only 8.8% of the trials discussed. One possible solution
to this issue would be to pass legislation providing the FDA with
the authority to mandate pharmaceutical companies to complete
testing of any medications that would likely be used by the preg-
nant population. An additional approach would be increasing the
support of pharmacokinetic trials in pregnancy by private and
by government-funded organizations. Government support for
existing disease-specific or pharmacology-related clinical research
networks charged to perform obstetric-fetal pharmacology studies
could be increased to allow for more sites, more basic/translational
studies, and more clinical trials. Another approach could be that
each NIH institute (NIDDK, NHLBI, NIAID, NICHD, NIMH,
etc.) maintain a certain percentage of pregnancy dosing-related
studies within its portfolio of supported studies.
In moving forward to incentivize, mandate, or simply encour-
age and support an increased number of pharmacokinetic studies
during pregnancy, the field of pediatrics provides one potential
model. Until recent years, similarly, dosing information was lack-
ing for most medications frequently administered to pediatric
patients. This problem is now slowly improving through a series of
government-based incentives and mandates (109–111). Both the
pediatric and pregnant populations face a reluctance to perform
clinical trials, in part due to legitimate ethical concerns. How-
ever, as pharmacotherapy must often be given in either group, the
result of not testing in these groups appears to be gradually gain-
ing recognition as an equally legitimate ethical concern. Hopefully,
the field of obstetrical pharmacology will be able to make similar
or more progress as the pediatric pharmacology field in the near
future.
This brief, focused review did not capture all pharmacoki-
netic studies during the time frame listed, as evidenced by the
44% increase in studies when the formal “clinical trial” filter was
removed. However, this was not designed as a comprehensive
meta-analysis. Rather, the goal was to provide a general overview
of trends over time and for various classes of drugs in order to raise
awareness of gaps in the literature and focus future efforts accord-
ingly. The inevitable shortcomings of the search strategy do not
change the overall findings relative to this goal. This review found
that the number of pharmacokinetic studies performed in preg-
nant women are exceedingly low, despite the fact that medication
use during pregnancy is widespread and increasing.
This review does not focus on pharmacodynamic studies. A
brief search using this term yields 828 studies in pregnancy since
2012 even with the restrictive “clinical trial” filter, but many of the
automated findings are surprisingly irrelevant to pharmacother-
apy and very few are related to dose determination. Many of the
dosing studies are for treatment given only at the time of deliv-
ery, such as pain control, for which outcome can be promptly
assessed. It is likely that there is a shortage of pharmacody-
namic studies in pregnancy, but further investigation is needed to
ascertain the scope of this problem. This issue is crucial, as with-
out accompanying pharmacodynamic data the pharmacokinetic
studies’ usefulness is limited.
An understanding of the clinical pharmacology of medications
during pregnancy is critical to develop optimal dosing regimens.
Inappropriate dosing of medications during pregnancy can have
minor to profound adverse consequences for both the mother and
the fetus. Increased number of studies and sources of support for
pharmacokinetic studies in pregnant women are greatly needed.
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